Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease

• DOI: 10.61919/5d02pk20
• Publication Date: 2025-06-01T01:12:39Z
• Authors: Syed Mohkumuddin; Muhammad Naseer; Muhammad Usman; Abdul Malik; Syed Akhter Muha...; Muhammad Azam

Background: Chronic kidney disease (CKD) increases susceptibility to hepatitis B and C infections, both of which complicate renal management elevate morbidity, particularly in populations with frequent healthcare exposures. There is limited real-world evidence on the efficacy safety modern antiviral regimens for these patients, especially low-resource settings. Objective: This study aimed evaluate effectiveness direct-acting antivirals virus (HCV) nucleus(t)ide analogues (HBV) patients CKD stages 3–5, focusing virologic response, function, adverse events. Methods: In this prospective observational cohort (n = 75), adults aged 18–65 years stage 3–5 chronic HBV or HCV, but without cirrhosis, HIV co-infection, prior transplantation, were consecutively recruited at two tertiary centers Pakistan between March 2024 February 2025. Antiviral included sofosbuvir-based DAAs HCV either tenofovir entecavir HBV, clinical laboratory assessment over 24 weeks. Primary outcomes sustained response (SVR12 HCV; undetectable DNA week 24) change eGFR; events monitored throughout. Ethical approval was obtained accordance Helsinki Declaration. Statistical analysis employed SPSS v24 chi-square paired t-tests as appropriate. Results: Among 75 participants (mean age 53.2 years), SVR12 achieved 95.2% suppression 87.9% cases. no significant mean eGFR (baseline 43.6 ± 12.7 vs. post-treatment 42.8 13.1; p 0.382), event rates low (9.3%), serious hepatic complications reported. Conclusion: Modern therapy delivers high biochemical normalization adversely affecting supporting their routine use nephrology care improving high-risk